Evitria AG and PE backed CDMOs: Insights from BioPlan Associates report

As evitria AG is owned by private equity Patricia Industries, it is always interesting to analyze what other PE backed investments are going on in that area. I have compiled a full overview of transactions affecting #CDMOs in my article in BioPlan Associates, Inc. 22nd Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production https://lnkd.in/eNSFgrMB. Thank you Donnie E. Gillespie to include me again in this industry leading documentation full of interesting facts and statistics. The survey collected extremely valuable data and is regarded as the industrial reference - just to name a few interesting examples here: For instance, it is reported that ≥90% of the world’s mammalian cell culture capacity is utilized for #antibody production, or that the average titer of commercial scale mAb production is still relatively low at 3.1 g/L and 3.9 g/L overall for all development stages – far away from individual cases with titers in the 8-12 g/L range. Therefore, it is not surprising to see that “improving the production titer” ranked second in factors to reduce COGS. Interestingly the average cost for recombinant proteins was ~300 $/g, although almost 25% of the analyzed facilities could achieve costs below 100 $/g. However, costs of >100 K$ annually per antibody treatment are not necessarily related to expensive manufacturing, but rather to high and frequent doses. But check it out yourself to find other interesting facts about bioprocessing.